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Abstract Screening for Chlamydia trachomatis-specific
antibodies is valuable in investigating recurrent miscar-
riage, tubal infertility and extrauterine pregnancy. We
compared here the performance of immunofluorescence
(IF) to four other commercial tests in detecting IgG
antibodies directed against C. trachomatis: two enzyme-
linked immunosorbent assays (ELISAs) using the major
outer membrane protein (MOMP) as the antigen, commer-
cialised respectively by Medac and R-Biopharm (RB), one
ELISA using the chlamydial heat shock protein 60
(cHSP60) as the antigen (Medac), as well as a new
automated epifluorescence immunoassay (InoDiag). A total
of 405 patients with (n=251) and without (n=154)
miscarriages were tested by all five tests. The prevalence
of C. trachomatis-specific IgG antibodies as determined by
the IF, cHSP60-Medac, MOMP-Medac, MOMP-RB and
InoDiag was 14.3, 23.2, 14.3, 11.9 and 26.2%, respectively.
InoDiag exhibited the highest sensitivity, whereas MOMP-
RB showed the best specificity. Cross-reactivity was
observed with C. pneumoniae using IF, MOMP-RB and
InoDiag, and Parachlamydia acanthamoebae using the
cHSP60 ELISA test. No cross-reactivity was observed
between C. trachomatis and the other Chlamydiales
(Neochlamydia hartmannellae, Waddlia chondrophila and
Simkania negevensis). Given its high sensitivity, the new
automated epifluorescence immunoassay from InoDiag
represents an interesting alternative. The MOMP-based
ELISA of R-Biopharm should be preferred for large
serological studies, given the high throughput of ELISA
and its excellent specificity.
Introduction
Chlamydia trachomatis is the most common sexually
transmitted bacterial infection in the world [1, 2]. In the
majority of cases, C. trachomatis infection is asymptomatic
[1]. Thus, few infected people seek medical care and
treatment, resulting in continued transmission to sexual
partners [1]. This explains the relatively high and increasing
prevalence of C. trachomatis infection throughout the
world, including countries with advanced medical care
and public health programmes [3–7]. Chlamydial infection
may cause urethritis, epididymitis, prostatitis, cervicitis,
pelvic inflammatory disease, ectopic pregnancy and tubal
infertility [2]. Chlamydial infection also increases the risk
of acquisition of human immunodeficiency virus (HIV) [2,
8], has been associated with cervical cancer [9] and may
induce severe adverse pregnancy outcomes [10, 11].
Serologic testing for C. trachomatis has been used to
detect antichlamydial antibodies among women with tubal
infertility [12, 13]. C. trachomatis serology is also useful to
investigate women with ectopic pregnancies [14], recurrent
miscarriages [10] and pelvic inflammatory disease (PID)
[15]. The microimmunofluorescence assay (IF) is consid-
ered to be the ‘gold standard’ for the serological diagnosis
of C. trachomatis infections [16]. However, IF is labour-
intensive and reading of the assay is operator-dependant
and subjective. To overcome these drawbacks, C. tracho-
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matis-specific enzyme-linked immunosorbent assay
(ELISA) tests have been developed, allowing large epide-
miological studies to be performed. These ELISA generally
use recombinant peptides of the major outer membrane
protein (MOMP) or the 60-kDa chlamydial heat shock
protein (cHSP60). A number of studies have demonstrated
strong correlations between the presence of anti-MOMP
antibodies [17–21] or cHSP60 [22–24] and the severity of
genital C. trachomatis disease, PID, infertility and tubal
pathology.
More recently, a new automated technique for the
simultaneous testing and detection of C. trachomatis, as
well as C. pneumoniae and C. psittaci, has been developed
by InoDiag (Signes, France). This multiplex serology
approach has already been used for the serodiagnosis of
atypical pneumonia [25] and blood culture-negative endo-
carditis [26]. The InoDiag serological test uses calibrated
antigens made of whole bacteria and is based on automated
incubation, reading and results interpretation of this ‘micro-
array’ serology [27]. As several antigens may be tested
simultaneously, this new test leads to decreased labour time
and, thus, reduced costs [25, 26, 28].
The present study aimed at comparing the performance
of five commercially available chlamydial IgG antibody
methods, including IF, three different ELISA tests, as well
as the new automated InoDiag serological test. Antibody
cross-reactivity with other related pathogens was also
assessed. Finally, the association between miscarriage and
Chlamydia seropositivity was also investigated.
Materials and methods
Patient population
Sera were obtained from women attending the Recurrent
Miscarriage Clinic at St. Mary’s Hospital, London. These
sera from 405 patients with (n=251) and without (n=
154) miscarriages had already been investigated for
Coxiella burnetii, Brucella abortus, Waddlia chondrophila
and Parachlamydia acanthamoebae as part of two
previous studies [29, 30]. Women without miscarriages
were used as negative controls to assess the association
between a positive C. trachomatis-positive serology and
miscarriage.
Serological assays for C. trachomatis
The following five serological assays were compared: C.
trachomatis IgG immunofluorescence (Micro IF Test,
ANILabsystems, Vantaa, Finland), two C. trachomatis
IgG ELISA both using the MOMP as the antigen (CT-
IgG-pELISA; Medac, Wedel, Germany, and CT pELISA;
R-Biopharm, Darmstadt, Germany), one ELISA using
cHSP60 as the antigen (cHSP60-IgG-pELISA; Medac,
Wedel, Germany) and a new automated epifluorescence
immunoassay (MuST Chlamydiae; InoDiag, Signes,
France). All five tests were performed according to the
manufacturers’ instructions. For clarity, these five tests
were respectively abbreviated as follow: IF, MOMP-Medac,
MOMP-RB, cHSP60-Medac and InoDiag.
InoDiag: a new automated epifluorescence immunoassay
The InoDiag test is an automated epifluorescence immuno-
assay that enable the simultaneous detection of C. tracho-
matis, C. pneumoniae and C. psittaci antibodies. Each
multiplexed slide also contained four controls: Staphylo-
coccus aureus ATCC 29213 to verify serum deposition,
human IgG (Serotec, Oxford, UK) to verify the secondary
antibody distribution and to detect the presence of
rheumatoid factor in patient sera, human IgA (Sigma, St.
Quentin Fallavier, France) to verify the secondary antibody
distribution and double-stranded DNA (Diarect, Freiburg,
Germany) to detect antinuclear antibodies in patient sera.
The multiplexed slide included three nanolitre spots
containing each of the following antigens: C. trachomatis
(ATCC VR-348-B), C. pneumoniae (ATCC VR-1310) and
C. psittaci (ATCC VR-601).
Four serum samples diluted at a ratio of 1:64 were tested
at the same time. Further remaining InoDiag reaction steps
(serum, secondary antibody addition, incubation, washing,
drying) were fully automated as previously described [25,
26]. The slides were then analysed by an automatic InoDiag
fluorescent camera analyser, allowing the simultaneous
detection of IgG and IgA directed against all antigens
tested. Finally, the data were automatically analysed for
each spot using the data-processing software Analarray 4.4-
1 (InoDiag).
Serological assays for other pathogens
Immunofluorescence slides from ANILabsystems used to
detect C. trachomatis antibodies also contained C. psittaci
and C. pneumoniae antigens, allowing the assessment of
cross-reactivity. Each slide was read blindly by two
independent observers.
In addition, an in-house IF assay was performed for W.
chondrophila (ATCC 1470), Simkania negevensis (ATCC
VR-1471), Neochlamydia hartmannellae (ATCC 50802)
and P. acanthamoebae strain BN9 (ATCC VR-1476), as
described previously [10, 29]. Briefly, sera were screened
by immunofluorescence using as a secondary antibody
FluolineH (bioMérieux, Marcy l’Etoile, France). Sera that
exhibited a total Ig titre ≥1:64 were then tested for IgG
reactivity using an anti-human IgG fluorescein (FluolineG,
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bioMérieux). Each immunofluorescence was read blindly
by two independent observers and congruent results were
considered to be positive. The IgG positivity cut-off was
≥1:64 [10, 29, 31].
Sera were also tested for the presence of antibodies
directed against C. burnetii using indirect immunofluores-
cence, as described previously [30]. B. abortus serological
diagnosis was established by Wright’s tube agglutination
test (Brucella Antigen, Sanofi Diagnostics, Marnes-la-
Coquette, France). Antibody reactivity against Toxoplasma
gondii was assessed using a commercial latex agglutination
kit, Toxo-Screen DA (bioMérieux).
Statistical analysis
To compare all five serological tests, the sensitivities,
specificities, positive predictive values (PPVs), negative
predictive values (NPVs), likelihood ratio for positive and
negative tests (LR+ or −) were calculated using Stata
(StataCorp, College Station, TX, USA) using different gold
standards. First, we considered IF as the gold standard.
Then, we used a combined gold standard based on the
results from all five serological tests. Since MOMP-RB
and MOMP-Medac are not completely independent tests,
we also used two additional combined gold standards,
respectively based on the results obtained with IF, cHSP60-
Medac and InoDiag, as well as only one of both MOMP-
based ELISA tests. Values in the grey zone (i.e. with
optical densities between the values threshold for negativ-
ity and positivity, as defined by the manufacturer of
cHSP60-Medac, MOMP-Medac and MOMP-RB) were
excluded from these analyses. To assess cross-reactivity,
we compared the correlation between serology directed
against two different pathogens using the Chi2 test. The
Chi2 test and logistic regression were used to assess the
presence of a correlation between C. trachomatis seropos-
itivity and miscarriage.
Results
Seroprevalence rates and concordance
Five different commercial serological tests were applied
to 405 sera taken from 405 different patients. The C.
trachomatis seroprevalence ranges from 11.8% with
MOMP-RB to 26.2% with InoDiag (Table 1). The
concordance of the C. trachomatis IgG results for all five
assays is shown in Table 2. A total of 183 (45.2%) of the
405 patients were positive with at least one of the five
serological tests, but only 20 (4.9%) were positive with all
five tests. In 203 (50.1%) cases, all five tests were
negative.
Test performances
Using IF as the gold standard, the sensitivities ranged from
48.1 to 63.8%, whereas the specificities ranged from 80.9
to 93.1%. The InoDiag test exhibited the best sensitivity
(63.8%), whereas MOMP-RB exhibited the best specificity
(93.1%).
A second analysis was conducted using another gold
standard based on the results from all five serological tests.
True-positive was defined as 4/5 or 5/5 tests positive. True-
negative was defined as 0/5 or 1/5 tests positive (i.e. 4/5 or
5/5 tests negative). Samples with indeterminate serology
(i.e. 3/5 tests positive and 2/5 tests negative [n=9] or 2/5
tests positive and 3/5 tests negative [n=26]) and samples in
the grey zone for at least one of the tests (n=46) were
excluded from the analysis. Using this new gold standard,
the sensitivities ranged from 83.3 to 100%, whereas the
specificities ranged from 87.4 to 99.7% (Table 3). Again,
the InoDiag test exhibited the best sensitivity (100%),
whereas MOMP-RB exhibited the best specificity (99.7%).
Even when indeterminate serologies were also included
(i.e. when true-positives were defined as three, four or five
positive tests and true-negatives were defined as three, four
or five negative tests), the InoDiag test exhibited the best
sensitivity, whereas MOMP-RB exhibited the best specific-
ity. Indeed, using this gold standard, sensitivities of 89.7,
92.3 and 97.4% and specificities of 95.9, 97.8 and 86.3%
were observed for MOMP-Medac, MOMP-RB and Ino-
Diag, respectively.
MOMP-Medac and MOMP-RB are using the same
antigen (MOMP) to detect C. trachomatis IgG. Thus, these
tests are not completely independent from each other and
the expanded gold standard may be biased. Thus, we also
Table 1 Results of Chlamydia trachomatis serologies using the five
serological tests
Serological tests Positive Negative Grey zone
n (%) n (%) n (%)
IFa 58 (14.3) 347 (85.7) – –
cHSP60-Medacb 94 (23.2) 292 (72.1) 19f (4.7)
MOMP-Medacc 58 (14.3) 336 (83.0) 11 (2.7)
MOMP-RBd 48 (11.8) 339 (83.7) 18f (4.4)
InoDiage 106 (26.2) 299 (73.8) – –
a IF = Micro IF Test (ANILabsystems, Vantaa, Finland)
b cHSP60-Medac = cHSP60-IgG-pELISA (Medac, Wedel, Germany)
cMOMP-Medac = CT-IgG-pELISA (Medac, Wedel, Germany)
dMOMP-RB = CT pELISA (R-Biopharm, Darmstadt, Germany)
e InoDiag = MuST Chlamydiae (InoDiag, Signes, France)
f Two sera were in the grey zone with both cHSP60-Medac and MOMP-
RB tests
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used two additional gold standards, respectively based on
the results obtained with all three of the other tests (IF,
cHSP60-Medac and InoDiag) and only one of the two
MOMP-based ELISA tests. With the gold standard defined
using MOMP-RB, IF, cHSP60-Medac and InoDiag, the test
exhibiting the highest performance in terms of sensitivity
and specificity was MOMP-RB, with a sensitivity of 97.1%
and a specificity of 99.3%. Conversely, with the gold
standard defined using MOMP-Medac, IF, cHSP60-Medac
and InoDiag, the test exhibiting the highest performance in
terms of sensitivity and specificity was MOMP-Medac,
with a sensitivity of 94.9% and a specificity of 96.7%.
Thus, the results obtained with these two additional gold
standards confirmed that, overall, MOMP-RB exhibits the
best performance.
Cross-reactions
Table 4 shows the cross-reactivities observed between C.
trachomatis and other related bacterial species according to
the serological test used. All five tests cross-reacted with C.
psittaci (p<0.001). IF, MOMP-RB and InoDiag also cross-
reacted with C. pneumoniae (p<0.001), whereas both
Medac tests did not cross-react with this pathogen. None
of the serological tests exhibited cross-reactivity with
Chlamydia-like organisms (W. chondrophila, P. acantha-
moebae, S. negevensis and N. hartmannellae), except for
cHSP60-Medac, which only cross-reacted with P. acantha-
Number of patients
n %
Positive with all five tests
IF/HSP60-Medac/MOMP-Medac/MOMP-RB/InoDiag 20 4.9
Positive with four tests 10 2.5
cHSP60-Medac/MOMP-Medac/MOMP-RB/InoDiag (not IF) 5 1.2
IF/MOMP-Medac/MOMP-RB/InoDiag (not cHSP60-Medac) 2 0.5
IF/cHSP60-Medac/MOMP-RB/InoDiag (not MOMP-Medac) 2 0.5
IF/cHSP60-Medac/MOMP-Medac/InoDiag (not MOMP-RB) 1 0.3
IF/cHSP60-Medac/MOMP-Medac/MOMP-RB (not InoDiag) 0 0.0
Positive with three tests 9 2.2
Positive with two tests 26 6.4
Positive with only one test 91 22.5
IF 13 3.2
cHSP60-Medac 37 9.1
MOMP-Medac 9 2.2
MOMP-RB 1 0.2
InoDiag 31 7.7
Negative with all five tests 203 50.1
Table 2 Concordance of C.
trachomatis IgG results with
the five serological testsa
a Samples in the grey zone for at
least one of the tests (n=46) were
excluded from the analysis
Table 3 Performance of the five serological tests using all tests as the
reference. True-positive was defined as 4/5 or 5/5 tests positive. True-
negative was defined as 0/5 or 1/5 tests positive (i.e. 4/5 or 5/5 tests
negative). Samples with indeterminable serology (i.e. 3/5 tests positive
and 2/5 tests negative [n=9] or 2/5 tests positive and 3/5 tests negative
[n=26]) and samples in the grey zone for at least one of the tests
(n=46) were excluded from the analysis
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)
LR
+
LR
−
IF 83.3 95.6 65.8 98.3 18.8 0.17
cHSP60-Medac 93.3 87.4 43.1 99.2 7.4 0.08
MOMP-Medac 93.3 96.9 75.7 99.3 30.5 0.07
MOMP-RB 96.7 99.7 96.7 99.7 284 0.03
InoDiag 100 89.5 49.2 100 9.5 0
PPV = positive predictive value
NPV = negative predictive value
LR+ = likelihood ratio for positive test
LR− = likelihood ratio for negative test
Table 4 Cross-reactions with other related bacterial species
C. pneumoniae C. psittaci P. acanthamoebae
IF ++ ++
cHSP60-Medac ++ +
MOMP-Medac ++
MOMP-RB ++ ++
InoDiag ++ ++
+ = p<0.05
++ = p<0.001
672 Eur J Clin Microbiol Infect Dis (2010) 29:669–675
moebae BN9 (p<0.05). There were no statistically signif-
icant cross-reactivities between C. trachomatis and T.
gondii, B. abortus and C. burnetii (p>0.05).
Association between miscarriage and C. trachomatis
seropositivity
A correlation between miscarriage and the presence of anti-
C. trachomatis IgG antibodies was observed when using IF
(9.6% versus 22.1%, p<0.001, odds ratio [OR] 2.68, 95%
confidence interval [CI] 1.52–4.73), MOMP-Medac (8.5%
versus 18.7%, p=0.005, OR 2.47, 95%CI 1.29–4.76) and
MOMP-RB (6.8% versus 15.9%, p=0.008, OR 2.61, 95%
CI 1.26–5.41). Although not reaching significance, a
similar trend was observed when using InoDiag (22.7%
versus 28.3%, p=0.217, OR 1.34, 95%CI 0.84–2.14) and
cHSP60-Medac (19.1% versus 27.6%, p=0.057, OR 1.62,
95%CI 0.98–2.67).
Discussion
This study compared the performance of five commercially
available tests for the detection of C. trachomatis IgG
antibodies, including a new automated multiplex antigen
microarray, developed by InoDiag for the detection of C.
trachomatis antibodies. Considerable inter-assay variability
was found in the number of patients with positive serology.
Previous studies comparing C. trachomatis ELISA to IF
have not reported such a large inter-assay variability [17,
20, 21, 32].
In the present study, seroprevalence rates were similar
for IF and MOMP tests (11.8–14.3%), whereas InoDiag
and cHSP60-Medac exhibited higher seroprevalences
(23.2–26.2%), possibly due to a higher rate of false-
positive results. ELISA MOMP-RB exhibited the best
sensitivity/specificity ratio in our study. This is congruent
with previous studies that showed the good sensitivities and
specificities of ELISA tests based on peptides from the
MOMP of C. trachomatis [20, 32]. Additional advantages
of these ELISA assays are: (i) their high throughput due to
their 96-well format, especially useful for large epidemio-
logical studies, and (ii) their objective reading of the results.
The new automated epifluorescence immunoassay from
InoDiag exhibited an apparently lower specificity than the
ELISA tests. However, given its high sensitivity and high
NPV in the present study, it may be used to screen patients
suffering from tubal infertility or miscarriage, especially to
rule out a possible role of C. trachomatis in the pathogen-
esis of these conditions. The flexibility of the machine
allowing batches of two to four samples is particularly
designed for a laboratory carrying a small number of tests
per pathogen. The automated microarray could test several
pathogens simultaneously, allowing pathology-driven test-
ing instead of the common pathogen-driven testing [28].
Such antigen microarrays have already been used success-
fully for the simultaneous detection of specific aetiological
pathogens of community-acquired pneumonia [25, 27] and
culture-negative endocarditis [26]. Concerning pregnancy,
this technique might be particularly useful to determine the
serological status at the beginning of the pregnancy for
various pathogens such as T. gondii, Treponema pallidum,
rubella virus, cytomegalovirus, herpes, HIV, HBV and
HCV. In the case of recurrent miscarriage and/or infertility,
the simultaneous determination of anti-C. trachomatis, anti-
W. chondrophila and anti-Coxiella antibodies, as well as
rheumatoid factor and antiphospholipid antibodies, might
greatly hasten diagnostic investigations. Additional benefits
include rapid time to results, semi-quantitative antibody
detection and low sera volume requirements.
The serological cross-reactivity between different Chla-
mydia species is well established [20, 33–35]. In one study
of patients attending STD clinics, antibodies directed
against two chlamydial antigens were found in 19 to 33%
of patients, and 33 to 40% of sera reacted with antigens of
these three species: C. trachomatis, C. pneumoniae and C.
psittaci [35]. In the present study, all C. trachomatis tests
cross-reacted with C. psittaci. IF and InoDiag tests also
significantly cross-reacted with C. pneumoniae. Since both
tests are using the whole elementary bodies of C.
trachomatis, the observed cross-reactions are likely to be
due to genus-reactive antigens exposed on the surface of
the bacteria. MOMP-RB also exhibited cross-reactivity
with C. pneumoniae, whereas MOMP-Medac failed to
show such cross-reactivity, although both tests use the
MOMP of C. trachomatis as the antigen. Similar observa-
tions were obtained by others [17, 20]. The information
provided by the manufacturers about the antigenic epitopes
used in their tests are very limited. Serotype-specific
determinants differ between tests and may explain the
differences found in the test performances between ELISA
tests from different manufacturers. Furthermore, tests based
on highly specific peptides may be so specific that they are
not able to detect all relevant antigens [20, 36]. Finally,
different mutations within MOMP and variants of serotypes
have been identified in urogenital isolates [37].
Previous studies have suggested an association between C.
trachomatis-positive serology and miscarriage [10, 11, 29].
In the present work, we confirmed this association using IF,
MOMP-Medac and MOMP-RB. Using cHSP60-Medac and
InoDiag, a trend towards a higher seroprevalence in the
miscarriage group was observed that did not reach signifi-
cance, likely due to the high seropositivity rate in the control
group due to the lower specificity of these two tests.
In conclusion, all of the serological assays tested here
performed as well as or even better than the IF assay for C.
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trachomatis IgG detection. Since ELISA-based serological
assays are well standardised, less time-consuming, less
expensive and less labourious than IF, they might be good
alternatives to IF for the detection of C. trachomatis an-
tibodies, especially when a large number of samples are to
be processed. The new automated epifluorescence immu-
noassay from InoDiag appears to be a promising assay,
given its excellent sensitivity and its microarray format that
enables the simultaneous testing of several pathogens.
Acknowledgements We thank Sébastien Aeby for the technical help
and André Baud for the computer assistance. David Baud is supported
by the “Société Académique Vaudoise” through the “Paul Blanc”
grant and the SICPA Foundation. Lesley Regan is grateful for support
from the NIHR Biomedical Research Centre Funding Scheme.
Research performed by the Greub Group is currently supported by
the Swiss National Science Foundation (grant nos. FN 3200BO-
116445 and 124483), by the Infectigen Foundation (In010), by the
University of Lausanne and by SUEZ-ONDEO (Paris, France).
Gilbert Greub is supported by the Leenards Foundation through a
“Bourse Leenards pour la relève académique en médecine clinique à
Lausanne”.
References
1. Peipert JF (2003) Clinical practice. Genital chlamydial infections.
N Engl J Med 349:2424–2430
2. Manavi K (2006) A review on infection with Chlamydia
trachomatis. Best Pract Res Clin Obstet Gynaecol 20:941–951
3. Spiliopoulou A, Lakiotis V, Vittoraki A, Zavou D, Mauri D (2005)
Chlamydia trachomatis: time for screening? Clin Microbiol Infect
11:687–689
4. Fine D, Dicker L, Mosure D, Berman S (2008) Increasing
chlamydia positivity in women screened in family planning
clinics: do we know why? Sex Transm Dis 35:47–52
5. Baud D, Jaton K, Bertelli C, Kulling JP, Greub G (2008) Low
prevalence of Chlamydia trachomatis infection in asymptomatic
young Swiss men. BMC Infect Dis 8:45
6. Lind I, Bollerup AC, Farholt S, Hoffmann S (2009) Laboratory
surveillance of urogenital Chlamydia trachomatis infections in
Denmark 1988–2007. Scand J Infect Dis 41:334–340
7. Kløvstad H, Aavitsland P (2009) Chlamydia trachomatis infec-
tions in Norway, 1986 to 2006, surveillance data. Sex Transm Dis
36:17–21
8. Sangani P, Rutherford G, Wilkinson D (2004) Population-based
interventions for reducing sexually transmitted infections, includ-
ing HIV infection. Cochrane Database Syst Rev 2:CD001220
9. Simonetti AC, Melo JH, de Souza PR, Bruneska D, de Lima Filho
JL (2009) Immunological’s host profile for HPV and Chlamydia
trachomatis, a cervical cancer cofactor. Microbes Infect 11:435–
442
10. Baud D, Regan L, Greub G (2008) Emerging role of Chlamydia
and Chlamydia-like organisms in adverse pregnancy outcomes.
Curr Opin Infect Dis 21:70–76
11. Mårdh PA (2002) Influence of infection with Chlamydia tracho-
matis on pregnancy outcome, infant health and life-long sequelae
in infected offspring. Best Pract Res Clin Obstet Gynaecol
16:847–864
12. Arya R, Mannion PT, Woodcock K, Haddad NG (2005) Incidence
of genital Chlamydia trachomatis infection in the male partners
attending an infertility clinic. J Obstet Gynaecol 25:364–367
13. den Hartog JE, Lardenoije CM, Severens JL, Land JA, Evers JL,
Kessels AG (2008) Screening strategies for tubal factor subfertil-
ity. Hum Reprod 23:1840–1848
14. Machado AC, Guimarães EM, Sakurai E, Fioravante FC, Amaral
WN, Alves MF (2007) High titers of Chlamydia trachomatis
antibodies in Brazilian women with tubal occlusion or previous
ectopic pregnancy. Infect Dis Obstet Gynecol 24816
15. Ness RB, Soper DE, Richter HE, Randall H, Peipert JF, Nelson
DB, Schubeck D, McNeeley SG, Trout W, Bass DC, Hutchison K,
Kip K, Brunham RC (2008) Chlamydia antibodies, chlamydia
heat shock protein, and adverse sequelae after pelvic inflammatory
disease: the PID Evaluation and Clinical Health (PEACH) Study.
Sex Transm Dis 35:129–135
16. Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS,
Guarner J, Hammerschlag MR, Jackson LA, Kuo CC, Maass M,
Messmer TO, Talkington DF, Tondella ML, Zaki SR (2001)
Standardizing Chlamydia pneumoniae assays: recommendations
from the Centers for Disease Control and Prevention (USA) and
the Laboratory Centre for Disease Control (Canada). Clin Infect
Dis 33:492–503
17. Jones CS, Maple PA, Andrews NJ, Paul ID, Caul EO (2003)
Measurement of IgG antibodies to Chlamydia trachomatis by
commercial enzyme immunoassays and immunofluorescence in
sera from pregnant women and patients with infertility, pelvic
inflammatory disease, ectopic pregnancy, and laboratory diag-
nosed Chlamydia psittaci/Chlamydia pneumoniae infection. J Clin
Pathol 56:225–229
18. Mouton JW, Peeters MF, van Rijssort-Vos JH, Verkooyen RP
(2002) Tubal factor pathology caused by Chlamydia trachomatis:
the role of serology. Int J STD AIDS 13(Suppl 2):26–29
19. Verkooyen RP, Peeters MF, van Rijsoort-Vos JH, van der Meijden
WI, Mouton JW (2002) Sensitivity and specificity of three new
commercially available Chlamydia trachomatis tests. Int J STD
AIDS 13(Suppl 2):23–25
20. Land JA, Gijsen AP, Kessels AG, Slobbe ME, Bruggeman CA
(2003) Performance of five serological chlamydia antibody tests
in subfertile women. Hum Reprod 18:2621–2627
21. Bax CJ, Mutsaers JA, Jansen CL, Trimbos JB, Dörr PJ, Oostvogel
PM (2003) Comparison of serological assays for detection of
Chlamydia trachomatis antibodies in different groups of obstetrical
and gynecological patients. Clin Diagn Lab Immunol 10:174–176
22. Gazzard CM, Wood RN, Debattista J, Allan JA, Allan JM, Timms
P (2006) Use of a commercial assay for detecting the 60 kDa
chlamydial heat shock protein in a range of patient groups. Sex
Transm Dis 33:77–79
23. Dutta R, Jha R, Salhan S, Mittal A (2008) Chlamydia trachoma-
tis-specific heat shock proteins 60 antibodies can serve as
prognostic marker in secondary infertile women. Infection
36:374–378
24. Bax CJ, Dörr PJ, Trimbos JB, Spaargaren J, Oostvogel PM, Peña
AS, Morré SA (2004) Chlamydia trachomatis heat shock protein
60 (cHSP60) antibodies in women without and with tubal
pathology using a new commercially available assay. Sex Transm
Infect 80:415–416
25. Gouriet F, Levy PY, Samson L, Drancourt M, Raoult D (2008)
Comparison of the new InoDiag automated fluorescence multi-
plexed antigen microarray to the reference technique in the
serodiagnosis of atypical bacterial pneumonia. Clin Microbiol
Infect 14:1119–1127
26. Gouriet F, Samson L, Delaage M, Mainardi JL, Meconi S,
Drancourt M, Raoult D (2008) Multiplexed whole bacterial
antigen microarray, a new format for the automation of serodiag-
nosis: the culture-negative endocarditis paradigm. Clin Microbiol
Infect 14:1112–1118
27. Gouriet F, Drancourt M, Raoult D (2006) Multiplexed serology in
atypical bacterial pneumonia. Ann NY Acad Sci 1078:530–540
674 Eur J Clin Microbiol Infect Dis (2010) 29:669–675
28. Raoult D, Fournier PE, Drancourt M (2004) What does the future
hold for clinical microbiology? Nat Rev Microbiol 2:151–159
29. Baud D, Thomas V, Arafa A, Regan L, Greub G (2007) Waddlia
chondrophila, a potential agent of human fetal death. Emerg Infect
Dis 13:1239–1243
30. Baud D, Peter O, Langel C, Regan L, Greub G (2009)
Seroprevalence of Coxiella burnetii and Brucella abortus among
pregnant women. Clin Microbiol Infect 15:499–501
31. Corsaro D, Greub G (2006) Pathogenic potential of novel
Chlamydiae and diagnostic approaches to infections due to these
obligate intracellular bacteria. Clin Microbiol Rev 19:283–297
32. Morré SA, Munk C, Persson K, Krüger-Kjaer S, van Dijk R, Meijer
CJ, van den Brule AJ (2002) Comparison of three commercially
available peptide-based immunoglobulin G (IgG) and IgA assays to
microimmunofluorescence assay for detection of Chlamydia tracho-
matis antibodies. J Clin Microbiol 40:584–587
33. Gnarpe J, Nääs J, Lundbäck A (2000) Comparison of a new
commercial EIA kit and the microimmunofluorescence technique
for the determination of IgG and IgA antibodies to Chlamydia
pneumoniae. APMIS 108:819–824
34. Messmer TO, Martinez J, Hassouna F, Zell ER, Harris W, Dowell
S, Carlone GM (2001) Comparison of two commercial micro-
immunofluorescence kits and an enzyme immunoassay kit for
detection of serum immunoglobulin G antibodies to Chlamydia
pneumoniae. Clin Diagn Lab Immunol 8:588–592
35. Bergström K, Domeika M, Vaitkiene D, Persson K, Mårdh PA
(1996) Prevalence of Chlamydia trachomatis, Chlamydia psittaci
and Chlamydia pneumoniae antibodies in blood donors and
attendees of STD clinics. Clin Microbiol Infect 1:253–260
36. Bas S, Muzzin P, Ninet B, Bornand JE, Scieux C, Vischer TL
(2001) Chlamydial serology: comparative diagnostic value of
immunoblotting, microimmunofluorescence test, and immuno-
assays using different recombinant proteins as antigens. J Clin
Microbiol 39:1368–1377
37. Morré SA, Ossewaarde JM, Lan J, van Doornum GJ,
Walboomers JM, MacLaren DM, Meijer CJ, van den Brule AJ
(1998) Serotyping and genotyping of genital Chlamydia tracho-
matis isolates reveal variants of serovars Ba, G, and J as
confirmed by omp1 nucleotide sequence analysis. J Clin Micro-
biol 36:345–351
Eur J Clin Microbiol Infect Dis (2010) 29:669–675 675
